Lexicon Investors Urge 5th Circ. To Revive Diabetes Drug Suit
Lexicon Pharmaceuticals investors urged a Fifth Circuit panel Wednesday to revive their lawsuit claiming the company overpromised on its ability to bring its prospective diabetes drug Zynquista to market, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article